细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2018.06.019

Abstract

Abstract: Cyclin-dependent kinase inhibitor 3(CDKN3)is a dual specificity phosphatase belonging to the CDC14s family.It has important clinical significance for early diagnosis, treatment and prognosis of tumors.The mechanism of CDKN3 in tumorigenesis and development has not yet been determined.Through reviewing the current research results, this paper summarizes the research progress of CDKN3 in tumors from four aspects:cell cycle regulation, apoptosis and migration & invasion, CDKN3 mutant and its subcellular localization.The direction provides a reference to promote the clinical transformation of CDKN3 and improve the clinical diagnosis and treatment of tumors.

Key words: CDKN3, Cell proliferation, Tumors

CLC Number:

LIU Juan, ZHANG Shutian. Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 575-578.

References

1 Kenji T.Development of cell-cycle checkpoint therapy for solid tumors[J].Jpn J Clin Oncol, 2015, 45(12):1097-1102.
2 Otto T, Sicinski P.Cell cycle proteins as promising targets in cancer therapy[J].Nat Rev Cancer, 2017, 17(2):93-115.
3 Hannon GJ, Casso D, Beach D.KAP:A dual specificity phosphatase that interacts with cyclin-dependent kinases[J].Proc Natl Acad Sci U S A, 1994, 91(5):1731-1735.
4 Demetrick DJ, Matsumoto S, Hannon GJ, et al.Chromosomal mapping of the genes for the human cell cycle proteins cyclin C(CCNC), cyclin E(CCNE), p21(CDKN1)and KAP(CDKN3)[J].Cytogenet Cell Genet, 1995, 69(3/4):190-192.
5 Alonso A, Sasin J, Bottini N, et al.Protein tyrosine phosphatases in the human genome[J].Cell, 2004, 117(6):699-711.
6 Yu Y, Jiang X, Schoch BS, et al.Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma[J].Cancer Res, 2007, 67(1):130-138.
7 Li H, Jiang X, Yu Y, et al.KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway[J].Oncogene, 2015, 34(11):1432-1441.
8 Chen Q, Chen K, Guo G, et al.A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis[J].PLoS One, 2014, 9(10):e111611.
9 Niculescu MD, Yamamuro Y, Zeisel SH.Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene[J].J Neurochem, 2004, 89(5):1252-1259.
10 Xing C, Xie H, Zhou L, et al.Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation[J].Biochem Biophys Res Commun, 2012, 420(1):29-35.
11 Zang X, Chen M, Zhou Y, et al.Identifying CDKN3 gene expression as a prognostic biomarker in lung adenocarcinoma via meta-analysis[J].Cancer Inform, 2015, 14(Suppl 2):183-191.
12 Zhang LP, Li WJ, Zhu YF, et al.CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer[J].Int J Clin Exp Pathol, 2015, 8(5):4535-4544.
13 Barrón EV, Roman-Bassaure E, Sánchez-Sandoval AL, et al.CDKN3 mRNA as a biomarker for survival and therapeutic target in cervical cancer[J].PLoS One, 2015, 10(9):e0137397.
14 Li Y, Ji S, Fu LY, et al.Knockdown of cyclin-dependent kinase inhibitor 3 inhibits proliferation and invasion in human gastric cancer cells[J].Oncol Res, 2017, 25(5):721-731.
15 Lai MW, Chen TC, Pang ST, et al.Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells[J].Urol Oncol, 2012, 30(6):871-878.
16 Deng M, Wang J, Chen Y, et al.Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines[J].Mol Med Rep, 2016, 14(2):1523-1530.
17 Pita JM, Figueiredo IF, Moura MM, et al.Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas[J].J Clin Endocrinol Metab, 2014, 99(3):497-507.
18 Yu C, Cao H, He X, et al.Cyclin-dependent kinase inhibitor 3(CDKN3)plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling[J].Biomed Pharmacother, 2017, 96:1109-1118.
19 Berumen J, Espinosa AM, Medina I.Targeting CDKN3 in cervical cancer[J].Expert Opin Ther Targets, 2014, 18(10):1149-1162.
20 Dai W, Miao H, Fang S, et al.CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma[J].Mol Med Rep, 2016, 14(2):1509-1514.
21 Brown NR, Noble ME, Lawrie AM, et al.Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity[J].J Biol Chem, 1999, 274(13):8746-8756.
22 Nalepa G, Barnholtz-Sloan J, Enzor R, et al.The tumor suppressor CDKN3 controls mitosis[J].J Cell Biol, 2013, 201(7):997-1012.
23 Srinivas V, Kitagawa M, Wong J, et al.The tumor suppressor CDKN3 is required for maintaining the proper number of centrosomes by regulating the centrosomal stability of Mps1[J].Cell Rep, 2015, 13(8):1569-1577.
24 Yang C, Sun JJ.Mechanistic studies of cyclin-dependent kinase inhibitor 3(CDKN3)in colorectal cancer[J].Asian Pac J Cancer Prev, 2015, 16(3):965-970.
25 Liu D, Zhang J, Wu Y, et al.YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway[J].Int J Cancer, 2018, 142(7):1392-1404.
26 Yeh CT, Lu SC, Chen TC, et al.Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma[J].Cancer Res, 2000, 60(17):4697-4700.
27 Yeh CT, Lu SC, Chao CH, et al.Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant[J].Biochem Biophys Res Commun, 2003, 305(2):311-314.
28 Lin WR, Lai MW, Yeh CT.Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth[J].Oncol Rep, 2013, 29(3):903-910.

[1]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[2]	YUAN Guixia, LI Yan, FENG Wanqi, XIA Xiaojuan, LI Xu. Mechanism of tumor suppressor gene DKK2 inhibiting proliferation of nephroblastoma cells in children [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 14-20.
[3]	DING Jiexian, ZHANG Jin, CHEN Yonggang, WANG Xingwen, WANG Shuanke. Progress in Wnt signaling pathway and tumorigenesis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 73-77.
[4]	HAN Bangling, WANG Yimin, XUE Yingwei. Research progress of vitamin D in tumors of digestive system [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 471-475.
[5]	WU Qirun,LUO Ting,WANG Peng,XU Ke. Application and prospect of nutritional support in advanced cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 381-384.
[6]	ZHOU Jie, CHEN Yu, CHEN Daozhen. Application of nanoparticles in photodynamic therapy of tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 245-249.
[7]	ZHANG Yongxin, HUANG He. Research progress and mechanism of Galectin-9 and various malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 159-163.
[8]	HAN Xuejiao, LI Yanchun, SUN lichun, LU Hailing. Research progress of the relationship between 14-3-3ζ and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 543-547.
[9]	JIANG Ying, LIU Baogang. Research progress of RCAN1 in malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 559-563.
[10]	TANG Mengmeng, LIU Tianbo, WANG Jing. Recent advances in prognosis of LMR associated with gynecological malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 569-572.
[11]	ZENG Kai,LIU Ming. Research progress of CBX protein and tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 165-169.
[12]	ZHANG Aiqi,JIN Shi,CAO Shoubo,YU Yan. Prognostic value of lymphocyte-to-monocyte ratio in the patients with malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 188-192.
[13]	FAN Mingxv, ZHAO Yanbin, LI Boyang, WANG Yan. Research progress in the Notch pathway in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 57-60.
[14]	WANG Peng, WANG Zheng, ZHOU Zhixiang. Roles of p53 in the interaction with digestive malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 468-472.
[15]	LI Guanghao, ZHANG Yubao. The research progress on NAMPT in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 158-161.

Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments